Every five years or so, the pharmaceutical industry rediscovers the patent cliff as though it is a new emergency. It […]

Every major pharmaceutical revenue event, from a blockbuster’s first generic competitor to a biosimilar’s delayed U.S. launch, traces back to

The single most valuable regulatory asset in the U.S. generic pharmaceutical industry is not a patent. It is the absence

Part I: The Architecture of Pharmaceutical Value — Patents as Financial Instruments What a Drug Patent Actually Is (And What

The $236 billion Loss of Exclusivity wave hitting between 2025 and 2030 is the most concentrated revenue erosion event in

Intellectual property has long been treated as a defensive asset — a legal shield erected around a discovery to keep

Introduction: The Paragraph IV Filing as Corporate Weapon A Paragraph IV certification is the most powerful offensive instrument in the

1. The Core Tension: Why Launch Pricing Breaks Finance Departments Pharmaceutical launch pricing is the only commercial decision in modern

The generic drug industry runs on a paradox. Generics fill more than 90% of all U.S. prescriptions yet account for